Endometrial cancers in mutation carriers from hereditary breast ovarian cancer syndrome kindreds

Murray J. Casey, Chhanda Bewtra, Henry T. Lynch, Carrie L. Snyder, Mark Stacey

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective The aim of this study was to categorize and report endometrial cancers in mutation carriers from hereditary breast ovarian cancer families. Methods Our Hereditary Cancer Registry was searched for gynecologic and peritoneal cancers linked to mutations in BRCA1 or BRCA2. Invasive cancers were registered in 101 mutation carriers with complete pathology reports. Efforts were made to secure diagnostic surgical pathology tissues for review. All records and available diagnostic slides were meticulously studied, and primary cancers were classified. Findings Eight malignancies were classified as primary endometrial cancers. Five of these were low- or intermediate-grade endometrioid carcinomas, and 3 were pure serous carcinomas or contained serous carcinoma elements mixed with high-grade endometrioid carcinoma. Breast cancers were diagnosed in 5 patients before and in 1 patient after endometrial carcinoma. Three endometrioid carcinomas were preceded by estrogen treatment, 2 for many years and the other for only 2 months, and 2 of the patients with serous carcinoma had been treated with tamoxifen. Conclusions The finding that 8 of gynecologic and peritoneal cancers in 101 mutation carriers were endometrial cancers with a smaller proportion of endometrioid carcinomas than reported in general populations is added to the current controversial literature on endometrial cancer, particularly regarding serous carcinomas, in hereditary breast ovarian cancer syndrome. Well-designed prospective programs for standardized surgical and pathologic handling, processing, and reporting are essential for working out the pathogenesis, true risks, and best management of this disease in carriers of deleterious BRCA1 and BRCA2 germline mutations.

Original languageEnglish
Pages (from-to)650-656
Number of pages7
JournalInternational Journal of Gynecological Cancer
Volume25
Issue number4
DOIs
StatePublished - May 7 2015

Fingerprint

Hereditary Breast and Ovarian Cancer Syndrome
Endometrial Neoplasms
Endometrioid Carcinoma
Mutation
Carcinoma
Neoplasms
Breast Neoplasms
Surgical Pathology
Germ-Line Mutation
Risk Management
Tamoxifen
Ovarian Neoplasms
Registries
Estrogens
Pathology

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology
  • Oncology
  • Medicine(all)

Cite this

Endometrial cancers in mutation carriers from hereditary breast ovarian cancer syndrome kindreds. / Casey, Murray J.; Bewtra, Chhanda; Lynch, Henry T.; Snyder, Carrie L.; Stacey, Mark.

In: International Journal of Gynecological Cancer, Vol. 25, No. 4, 07.05.2015, p. 650-656.

Research output: Contribution to journalArticle

@article{cba8290944f94ae8bdd76b2e5118d357,
title = "Endometrial cancers in mutation carriers from hereditary breast ovarian cancer syndrome kindreds",
abstract = "Objective The aim of this study was to categorize and report endometrial cancers in mutation carriers from hereditary breast ovarian cancer families. Methods Our Hereditary Cancer Registry was searched for gynecologic and peritoneal cancers linked to mutations in BRCA1 or BRCA2. Invasive cancers were registered in 101 mutation carriers with complete pathology reports. Efforts were made to secure diagnostic surgical pathology tissues for review. All records and available diagnostic slides were meticulously studied, and primary cancers were classified. Findings Eight malignancies were classified as primary endometrial cancers. Five of these were low- or intermediate-grade endometrioid carcinomas, and 3 were pure serous carcinomas or contained serous carcinoma elements mixed with high-grade endometrioid carcinoma. Breast cancers were diagnosed in 5 patients before and in 1 patient after endometrial carcinoma. Three endometrioid carcinomas were preceded by estrogen treatment, 2 for many years and the other for only 2 months, and 2 of the patients with serous carcinoma had been treated with tamoxifen. Conclusions The finding that 8 of gynecologic and peritoneal cancers in 101 mutation carriers were endometrial cancers with a smaller proportion of endometrioid carcinomas than reported in general populations is added to the current controversial literature on endometrial cancer, particularly regarding serous carcinomas, in hereditary breast ovarian cancer syndrome. Well-designed prospective programs for standardized surgical and pathologic handling, processing, and reporting are essential for working out the pathogenesis, true risks, and best management of this disease in carriers of deleterious BRCA1 and BRCA2 germline mutations.",
author = "Casey, {Murray J.} and Chhanda Bewtra and Lynch, {Henry T.} and Snyder, {Carrie L.} and Mark Stacey",
year = "2015",
month = "5",
day = "7",
doi = "10.1097/IGC.0000000000000402",
language = "English",
volume = "25",
pages = "650--656",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Endometrial cancers in mutation carriers from hereditary breast ovarian cancer syndrome kindreds

AU - Casey, Murray J.

AU - Bewtra, Chhanda

AU - Lynch, Henry T.

AU - Snyder, Carrie L.

AU - Stacey, Mark

PY - 2015/5/7

Y1 - 2015/5/7

N2 - Objective The aim of this study was to categorize and report endometrial cancers in mutation carriers from hereditary breast ovarian cancer families. Methods Our Hereditary Cancer Registry was searched for gynecologic and peritoneal cancers linked to mutations in BRCA1 or BRCA2. Invasive cancers were registered in 101 mutation carriers with complete pathology reports. Efforts were made to secure diagnostic surgical pathology tissues for review. All records and available diagnostic slides were meticulously studied, and primary cancers were classified. Findings Eight malignancies were classified as primary endometrial cancers. Five of these were low- or intermediate-grade endometrioid carcinomas, and 3 were pure serous carcinomas or contained serous carcinoma elements mixed with high-grade endometrioid carcinoma. Breast cancers were diagnosed in 5 patients before and in 1 patient after endometrial carcinoma. Three endometrioid carcinomas were preceded by estrogen treatment, 2 for many years and the other for only 2 months, and 2 of the patients with serous carcinoma had been treated with tamoxifen. Conclusions The finding that 8 of gynecologic and peritoneal cancers in 101 mutation carriers were endometrial cancers with a smaller proportion of endometrioid carcinomas than reported in general populations is added to the current controversial literature on endometrial cancer, particularly regarding serous carcinomas, in hereditary breast ovarian cancer syndrome. Well-designed prospective programs for standardized surgical and pathologic handling, processing, and reporting are essential for working out the pathogenesis, true risks, and best management of this disease in carriers of deleterious BRCA1 and BRCA2 germline mutations.

AB - Objective The aim of this study was to categorize and report endometrial cancers in mutation carriers from hereditary breast ovarian cancer families. Methods Our Hereditary Cancer Registry was searched for gynecologic and peritoneal cancers linked to mutations in BRCA1 or BRCA2. Invasive cancers were registered in 101 mutation carriers with complete pathology reports. Efforts were made to secure diagnostic surgical pathology tissues for review. All records and available diagnostic slides were meticulously studied, and primary cancers were classified. Findings Eight malignancies were classified as primary endometrial cancers. Five of these were low- or intermediate-grade endometrioid carcinomas, and 3 were pure serous carcinomas or contained serous carcinoma elements mixed with high-grade endometrioid carcinoma. Breast cancers were diagnosed in 5 patients before and in 1 patient after endometrial carcinoma. Three endometrioid carcinomas were preceded by estrogen treatment, 2 for many years and the other for only 2 months, and 2 of the patients with serous carcinoma had been treated with tamoxifen. Conclusions The finding that 8 of gynecologic and peritoneal cancers in 101 mutation carriers were endometrial cancers with a smaller proportion of endometrioid carcinomas than reported in general populations is added to the current controversial literature on endometrial cancer, particularly regarding serous carcinomas, in hereditary breast ovarian cancer syndrome. Well-designed prospective programs for standardized surgical and pathologic handling, processing, and reporting are essential for working out the pathogenesis, true risks, and best management of this disease in carriers of deleterious BRCA1 and BRCA2 germline mutations.

UR - http://www.scopus.com/inward/record.url?scp=84928910997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928910997&partnerID=8YFLogxK

U2 - 10.1097/IGC.0000000000000402

DO - 10.1097/IGC.0000000000000402

M3 - Article

C2 - 25756400

AN - SCOPUS:84928910997

VL - 25

SP - 650

EP - 656

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 4

ER -